Three- and five-year overall survival similar with allogeneic or autologous HSCT, but transplant-related mortality higher with allogeneic HSCT<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, June 10, 2021 (HealthDay News) — For patients with refractory or relapsed peripheral T-cell lymphoma (R\/R-PTCL), three- and five-year overall survival (OS) and progression-free survival (PFS) are similar with allogeneic or autologous hematopoietic stem cell transplant (HSCT), but transplant-related mortality (TRM) is higher with allogeneic HSCT, according to a review published online May 27 in JAMA Network Open<\/em>.<\/p>\n Jun Du, M.D., from the Chinese Academy of Medical Sciences and Peking Union Medical College in Tianjin, China, and colleagues conducted a systematic review of the literature and meta-analysis to compare the effectiveness and safety of allogeneic HSCT versus autologous HSCT among patients with R\/R-PTCL. Thirty trials were included in the meta-analysis, with 880 and 885 patients undergoing allogeneic and autologous HSCT, respectively.<\/p>\n The researchers found that the three-year OS and PFS were 50 and 42 percent, respectively; five-year OS and PFS were 54 and 48 percent, respectively; and three-year TRM was 32 percent in the allogeneic HSCT group. The three-year OS and PFS were 55 and 41 percent, respectively; five-year OS and PFS were 53 and 40 percent, respectively; and three-year TRM was 7 percent in the autologous HSCT group.<\/p>\n “The data from this meta-analysis provide evidence that for select patients with PTCL, both autologous HSCT and allogeneic HSCT may be a potentially effective approach to treatment,” write the authors of an accompanying editorial. “This meta-analysis falls short of providing a rigorous, risk-segmented analysis of which modality is more likely to be most effective for a particular patient.”<\/p>\n Abstract\/Full Text<\/a><\/p>\n